Patient characteristics
| Sarcoidosis patients | Healthy subjects | p-value | |
| Subjects n | 32 | 40 | |
| Age years | 50±13 | 49±13 | 0.700 |
| Female | 20 (63) | 27 (68) | 0.457 |
| Ethnicity | |||
| Afro-Caribbean | 21 (66) | ||
| Caucasian | 8 (25) | ||
| South Asian# | 2 (6) | ||
| Other | 1 (3) | ||
| Smoking status | |||
| Current | 0 (0) | 0 (0) | |
| Ex (<10 pack-years) | 7 (22) | ||
| Never | 25 (78) | 40 (100) | |
| Organs involved | |||
| Lungs | 32 (100) | ||
| Skin | 15 (47) | ||
| Eyes | 6 (19) | ||
| Nervous system | 4 (13) | ||
| Bone and joints | 4 (13) | ||
| Organs involved n | 2±0 | ||
| FEV1 % pred | 72.2±19.1 | 97.0±28.2 | <0.001 |
| FVC % pred | 83.7±16.8 | 100.9±29.0 | <0.001 |
| TLCO % pred | 66.5±11.5 | ||
| Scadding stage | |||
| 0/I | 8 | ||
| II | 9 | ||
| III | 4 | ||
| IV | 11 | ||
| Immunosuppressant¶ | |||
| None | 19 (56) | ||
| Prednisolone | 10 (29) | ||
| Hydroxychloroquine | 3 (9) | ||
| Inhaled steroids | 2 (6) | ||
| Serum ACE level+ IU·L−1 | 75±37 |
Data presented as n (%) or mean±sd, unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLCO: transfer factor of the lung for carbon monoxide; ACE: angiotensin-converting enzyme. #: patients originating from India, Pakistan or Bangladesh; ¶: immunosuppressant medications were those prescribed at the time of the study; +: normal serum angiotensin-converting enzyme (ACE) level 52 IU·L−1.